- Home
- PHVS vs CCEC Comparison
PHVS vs CCEC Comparison
Compare PHVS & CCEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- CCEC
- Stock Information
- Founded
- PHVS 2015
- CCEC 2007
- Country
- PHVS Switzerland
- CCEC Greece
- Employees
- PHVS N/A
- CCEC N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- CCEC Marine Transportation
- Sector
- PHVS Health Care
- CCEC Consumer Discretionary
- Exchange
- PHVS Nasdaq
- CCEC Nasdaq
- Market Cap
- PHVS 1.6B
- CCEC 1.3B
- IPO Year
- PHVS 2021
- CCEC 2007
- Fundamental
- Price
- PHVS $23.24
- CCEC $21.90
- Analyst Decision
- PHVS Buy
- CCEC Buy
- Analyst Count
- PHVS 6
- CCEC 1
- Target Price
- PHVS $36.50
- CCEC $26.00
- AVG Volume (30 Days)
- PHVS 229.7K
- CCEC 13.8K
- Earning Date
- PHVS 11-12-2025
- CCEC 10-30-2025
- Dividend Yield
- PHVS N/A
- CCEC 5.50%
- EPS Growth
- PHVS N/A
- CCEC 62.73
- EPS
- PHVS N/A
- CCEC 4.04
- Revenue
- PHVS N/A
- CCEC $424,701,000.00
- Revenue This Year
- PHVS N/A
- CCEC $17.10
- Revenue Next Year
- PHVS N/A
- CCEC $13.73
- P/E Ratio
- PHVS N/A
- CCEC $5.40
- Revenue Growth
- PHVS N/A
- CCEC 84.28
- 52 Week Low
- PHVS $11.51
- CCEC $14.09
- 52 Week High
- PHVS $26.33
- CCEC $24.83
- Technical
- Relative Strength Index (RSI)
- PHVS 51.85
- CCEC 48.17
- Support Level
- PHVS $20.65
- CCEC $21.85
- Resistance Level
- PHVS $22.90
- CCEC $23.17
- Average True Range (ATR)
- PHVS 1.40
- CCEC 0.98
- MACD
- PHVS 0.05
- CCEC 0.02
- Stochastic Oscillator
- PHVS 74.86
- CCEC 39.13
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About CCEC Capital Clean Energy Carriers Corp. Common Share
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.